<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00807313</url>
  </required_header>
  <id_info>
    <org_study_id>RCT501</org_study_id>
    <nct_id>NCT00807313</nct_id>
  </id_info>
  <brief_title>Non-interventional Observational Study of Helical Tomotherapy for Oligometastatic Colorectal Cancer</brief_title>
  <acronym>tomoligo</acronym>
  <official_title>Non-interventional Observational Study of Helical Tomotherapy for Oligometastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitair Ziekenhuis Brussel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with oligometastatic colorectal cancer (5 metastases or less) receive a combination
      of systemic treatment and often local treatment, such as surgery, radiofrequency ablation and
      more recently stereotactic body radiotherapy. The aim of this study is to register the
      results and side effects of stereotactic body radiotherapy (SBRT) by means of helical
      tomotherapy in the treatment of oligometastatic colorectal cancer.

      The trial has two cohorts. Patients in cohort I get consolidation SBRT after best response on
      first line chemotherapy. Patients in cohort II get SBRT when there is progression under, or
      no indication for (further) chemotherapy. The primary endpoint is to evaluate the metabolic
      complete remission rate three months after the start of radiotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Metabolic complete remission rate</measure>
    <time_frame>Three months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute toxicity</measure>
    <time_frame>Three months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Three to thirty six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local control</measure>
    <time_frame>Three to thirty six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>Three to thirty six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late toxicity</measure>
    <time_frame>Three to thirty six months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">53</enrollment>
  <condition>Colon Cancer</condition>
  <condition>Rectal Cancer</condition>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>At best response</arm_group_label>
    <description>Patients with oligometastatic colorectal cancer, who presents at best response under chemotherapy, will receive stereotactic body radiotherapy on their residual disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No indication for chemotherapy</arm_group_label>
    <description>Patients with oligometastatic colorectal cancer, who are progressive under chemotherapy or who are no candidates for (further) chemotherapy, will receive stereotactic body radiotherapy on the sites of disease.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with oligometastatic (5 metastases or less) colorectal cancer
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with (residual) oligometastatic CRC: ≤ 5 mets

          -  Primary tumor treated with curative intention (surgery, radiotherapy,
             chemoradiotherapy)

          -  Functional liver volume &gt; 1000cc if livermets, lung DLCO &gt; 30% if lungmets.

          -  No Child B or C liver cirrhosis

          -  No contra-indications for radiation of all metastatic CRC (= no violation of
             constraints of organs at risk (OAR))

          -  No mets from another carcinoma

          -  Age &gt; 18 years

          -  WHO-PS ≤ 2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark De Ridder, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Brussel, Vrije Universiteit Brussel, dienst Radiotherapie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UZ Brussel, Vrije Universiteit Brussel, dienst Radiotherapie</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Verellen D, De Ridder M, Linthout N, Tournel K, Soete G, Storme G. Innovations in image-guided radiotherapy. Nat Rev Cancer. 2007 Dec;7(12):949-60. Review. Erratum in: Nat Rev Cancer. 2008 Jan;8(1):71.</citation>
    <PMID>18034185</PMID>
  </reference>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2008</study_first_submitted>
  <study_first_submitted_qc>December 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2008</study_first_posted>
  <last_update_submitted>April 29, 2013</last_update_submitted>
  <last_update_submitted_qc>April 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitair Ziekenhuis Brussel</investigator_affiliation>
    <investigator_full_name>Mark De Ridder</investigator_full_name>
    <investigator_title>Head of Radiotherapy Department</investigator_title>
  </responsible_party>
  <keyword>Oligometastatic disease</keyword>
  <keyword>Colorectal cancer</keyword>
  <keyword>Stereotactic body radiotherapy</keyword>
  <keyword>Tomotherapy</keyword>
  <keyword>Metabolic response</keyword>
  <keyword>Stage IV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

